- Home
- NBH vs PRQR Comparison
NBH vs PRQR Comparison
Compare NBH & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.33
Company Overview
Basic Information| Metric | NBH | PRQR |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.6M | 250.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NBH | PRQR |
|---|---|---|
| Price | $10.25 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | 85.9K | ★ 558.5K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | ★ $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $87.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.75 | $1.07 |
| 52 Week High | $11.01 | $3.46 |
Technical Indicators
Market Signals| Indicator | NBH | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 53.75 |
| Support Level | $10.22 | $2.15 |
| Resistance Level | $10.33 | $2.42 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 66.67 | 79.70 |
Price Performance
Historical Comparison NBH
PRQR
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.